David J. Fitzgerald
Senior Investigator
Laboratory of Molecular Biology
National Cancer Institute
United States of America
Biography
Dr. Fitzgerald is chief of the Biotherapy Section, Laboratory of Molecular Biology, in the NCI. He received his Ph.D. in 1982 from the University of Cincinnati Medical School, Department of Microbiology. The focus of his Ph.D. dissertation was the endocytic uptake of Pseudomonas exotoxin. He has a longstanding interest in bacterial toxins and their use as therapeutic agents.
Research Interest
1) Antibodies 2) toxins 3) cancer therapeutics 4) cell biology 5) immunotoxins 6) Cancer Biology, 7) Cell Biology, 8) Immunology, 9) Microbiology and Infectious Diseases, 10) Molecular Biology and Biochemistry
Publications
-
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
-
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
-
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.